B cell related predictive biomarkers of treatment response in myasthenia gravis

Myasthenia Gravis (MG) is a B cell-mediated autoimmune disease characterized by muscle weakness and fatigability, mostly associated to antibodies against the acetylcholine receptor (AChR). MG patients are chronically treated by immunosuppressants and 10–15% are treatment refractory. The purpose of our study is to identify changes in B-cell subsets that could predict treatment response in MG subgroups with different treatment-related status, with...